TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna and Merck reported Phase 3 results showing that intismeran, a personalized mRNA vaccine given with Keytruda, reduced the two-year risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. The companies also reported improved distant metastasis-free survival; longer-term results, regulatory plans and full trial details were not provided in the source material.
Moderna and Merck said a personalized mRNA vaccine given with Merck’s Keytruda reduced the two-year risk of melanoma recurrence or death by 42% compared with Keytruda and placebo in a Phase 3 trial. The companies reported that 82% of patients who received the vaccine combination were alive without recurrence at two years, versus 70% in the comparison group.
The vaccine, called intismeran or mRNA-4157, is tailored to a patient’s tumor. Researchers compare genetic material from cancer cells with healthy cells, select cancer-specific mutations and use synthetic mRNA to encode up to 34 mutations. The aim is to prompt an immune response directed at features of that individual’s cancer. Patients in the reported treatment group received intismeran with Keytruda; the comparison group received Keytruda with placebo.
The companies reported two measures of outcomes. Recurrence-free survival (RFS) measures time without cancer returning. At two years, 82% of patients in the vaccine group were alive without recurrence, compared with 70% in the Keytruda-placebo group. The reported 42% figure is a relative reduction in the risk of recurrence or death, not a 42-percentage-point difference in the share of patients without recurrence.
For distant metastasis-free survival (DMFS)—time without cancer returning in a distant part of the body—the companies said the vaccine combination reduced the risk of distant metastasis or death by 38% compared with Keytruda and placebo. At the reported assessment, 88.5% of the combination group were alive without distant metastasis, versus 80% of the comparison group. These figures and risk reductions are based on the companies’ announcement as described in the source report.
A Potential Addition After Melanoma Surgery
The results address treatment after a melanoma has been removed, when patients may still face a risk that the cancer will return or spread. Keytruda is already used in this setting. The reported benefit suggests that adding a vaccine designed around a patient’s own tumor could improve outcomes beyond the existing treatment, if the findings are confirmed and the approach becomes available for clinical use.
The difference in the two-year outcome rates offers a concrete way to understand the result: 82% versus 70% were alive without recurrence. That is a 12-percentage-point difference at that time point, while the companies’ 42% figure describes the relative reduction in risk. The measures are not interchangeable. Patients and clinicians would also need to weigh the treatment’s risks, logistics and access alongside the potential benefit; the supplied report does not provide enough detail to assess those issues.
The announcement describes the study as a Phase 3 result, a later-stage test of a treatment in patients. It could inform future regulatory and treatment decisions, but a trial result alone does not establish that the vaccine is approved, available or appropriate for every person with melanoma.
melanoma sunscreen broad spectrum SPF 50
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Personalized Vaccine Is Made
Unlike a vaccine designed to target one shared feature, intismeran is produced using mutations identified in an individual patient’s tumor. The researchers select mutations not found in the patient’s healthy cells and encode them in synthetic mRNA. The source report says the vaccine can include genetic coding for up to 34 tumor mutations, with the goal of guiding the immune system toward cancer-specific targets.
The new figures follow earlier findings from a Phase 2 trial with five years of follow-up. The source report says that study showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. The Phase 3 results described here were less pronounced on those relative-risk measures, but reported benefits on both RFS and DMFS compared with Keytruda alone.
The treatment is used alongside Keytruda, rather than presented as a replacement for it. The comparison in the reported trial was between the combination and Keytruda plus placebo, making the question whether the personalized vaccine adds benefit to that standard treatment.
“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma, setting a new benchmark in the adjuvant setting and representing one of the most significant advances in melanoma treatment since the advent of immunotherapy.””
— Dean Li, president of Merck Research Laboratories
UPF 50 sun protective clothing for skin cancer prevention
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Questions Beyond the Two-Year Results
The available report does not give the full trial publication, including the number of participants, confidence intervals, statistical significance details, adverse-event rates or the precise follow-up schedule. Those details are needed to assess how reliable and clinically meaningful the findings are across different patient groups. The reported percentages describe trial outcomes; they do not predict an individual patient’s result.
It is also unclear from the supplied material how long the benefit may persist beyond the two-year assessment, whether the results differ among patient subgroups, or what the vaccine’s treatment burden and side-effect profile were. The source describes the findings as an announcement by Moderna and Merck and does not provide regulatory decisions or an approval timeline. The comparison with the earlier Phase 2 results is informative, but the supplied information does not establish why the reported effect sizes differ.
As an affiliate, we earn on qualifying purchases.
Full Data and Regulatory Steps
The next key information will be a detailed account of the Phase 3 trial, including its methods, patient characteristics, safety results and statistical analyses. Publication or presentation of the full data would allow clinicians and independent researchers to examine the results beyond the headline risk reductions.
Any move toward regulatory review or changes in clinical practice would depend on further evidence and decisions by relevant authorities. The source material does not state when Moderna or Merck plans to submit the results, whether an application has been filed, or when patients might be able to receive the vaccine outside a clinical trial. For now, the confirmed development is the companies’ report of improved two-year outcomes in the trial, not a change in approved treatment guidance.
skin cancer self examination guide melanoma
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What does the 42% reduction mean?
It is the companies’ reported relative reduction in the risk of recurrence or death for patients receiving intismeran with Keytruda compared with Keytruda and placebo. It does not mean 42% more patients avoided recurrence; at two years, 82% of the vaccine group and 70% of the comparison group were alive without recurrence.
What is intismeran?
Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using mutations identified in a patient’s cancer cells. The source says it can encode up to 34 tumor mutations and was tested in combination with Keytruda.
Did the trial show fewer distant metastases?
The companies reported a 38% reduction in the risk of distant metastasis or death compared with Keytruda and placebo. At the reported assessment, 88.5% of the combination group were alive without distant metastasis, versus 80% of the comparison group.
Is the vaccine approved or available to patients?
The supplied report does not say that intismeran has been approved or provide a regulatory timeline. It reports Phase 3 results; availability and any change to treatment guidance remain unclear.
How do these results compare with the earlier study?
The source report says a five-year Phase 2 study found a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk. The Phase 3 figures reported here were 42% and 38%, respectively; the supplied information does not explain the difference.
Source: hn
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
